Darnige L. Diagnostic biologique du syndrome des antiphospholipides.
Rev Med Interne 2006;
27:296-301. [PMID:
16236386 DOI:
10.1016/j.revmed.2005.08.014]
[Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2005] [Accepted: 08/16/2005] [Indexed: 11/21/2022]
Abstract
PURPOSE
The antiphospholipid syndrome is a bioclinical entity defined by the occurrence of thromboses, and/or obstetrical complications in the persistent presence of antiphospholipid antibodies, i.e. lupus anticoagulant and/or anticardiolipin antibodies. This review focuses on the methods for antiphospholipid antibodies detection and their clinical usefulness.
CURRENT KNOWLEDGE AND KEY POINTS
Lupus anticoagulant is the strongest risk factor for thrombosis in antiphospholipid syndrome. Twenty years after its description, anticardiolipin ELISA, despite a still improvable standardization and its lack of specificity, is still required for sensitive diagnosis of antiphospholipid syndrome.
FUTURE PROSPECTS AND PROJECTS
A better knowledge of the beta-2-glycoprotein-I role in the pathophysiology of antiphospholipid syndrome might lead to the development of new markers of thrombotic risk.
Collapse